<![CDATA[Hansa Biopharma — Februar 2023]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/topic/400735/hansa-biopharma-februar-2023RSS for NodeSat, 06 Jun 2026 13:37:12 GMTWed, 01 Feb 2023 05:06:50 GMT60<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Tue, 28 Feb 2023 17:42:19 GMT]]>"Elisabeth Sonnesson, Global Franchise Lead Autoimmunity presented last week at Erik Pensers Healthcare Day focusing on autoimmune diseases. A very insightful presentation on the autoimmune space and the programs Hansa is currently investigating" https://proinvestor.com/boards/110967

]]>https://dev.proinvestor.com/forum/post/8006550https://dev.proinvestor.com/forum/post/8006550Tue, 28 Feb 2023 17:42:19 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Wed, 15 Feb 2023 15:35:44 GMT]]>Hansa Biopharma Automatisk teknisk analys. Medellång sikt, 14 feb 2023 (for dem som er til TA):

Link Preview Image
Hansa Biopharma - teknisk analys av aktien - Dagens industri

Utförlig grafisk information om Hansa Biopharma historiska utveckling som ger en hint om aktiens framtida utveckling.

favicon

Dagens industri (www.di.se)

(Dagens industri)

]]>https://dev.proinvestor.com/forum/post/8006549https://dev.proinvestor.com/forum/post/8006549Wed, 15 Feb 2023 15:35:44 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 11 Feb 2023 08:41:28 GMT]]>JA, vi er stadig i starten af S-kurven.

]]>https://dev.proinvestor.com/forum/post/8006547https://dev.proinvestor.com/forum/post/8006547Sat, 11 Feb 2023 08:41:28 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 11 Feb 2023 08:18:54 GMT]]>Redeye sänker motiverat värde för Hansa Biopharma till 170 kronor (410)

... "Analyshuset spår att försäljningen av Idefirix kommer att uppgå till 143 miljoner kronor i år och sedan öka till över 900 miljoner kronor år 2026." ...

Nyhetsbyrån Finwire

]]>https://dev.proinvestor.com/forum/post/8006544https://dev.proinvestor.com/forum/post/8006544Sat, 11 Feb 2023 08:18:54 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 11 Feb 2023 08:14:30 GMT]]>Fremtiden ser stadig lys ud..

]]>https://dev.proinvestor.com/forum/post/8006546https://dev.proinvestor.com/forum/post/8006546Sat, 11 Feb 2023 08:14:30 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 11 Feb 2023 08:13:36 GMT]]>Selvfølgelig lidt et gok i nødden, men da det jo, ihvertfald indtil nu, ikke har noget at gøre med om det de laver duer, men mere noget med timing, er det for mig at se, blot et realistisk perspektiv.

]]>https://dev.proinvestor.com/forum/post/8006545https://dev.proinvestor.com/forum/post/8006545Sat, 11 Feb 2023 08:13:36 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Fri, 10 Feb 2023 15:10:13 GMT]]>(Redeye RESEARCH UPDATE - 2023-02-10)

]]>https://dev.proinvestor.com/forum/post/8006541https://dev.proinvestor.com/forum/post/8006541Fri, 10 Feb 2023 15:10:13 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Fri, 10 Feb 2023 15:08:17 GMT]]>We make a slight negative revision after the recent Q4 result, and the most significant change is the number of shares relating to funding protecting the equity levels.
Our Base Case is SEK 170 (410) with a Bull Case of SEK 400 (600) and a Bear Case of SEK 45 (175).

]]>https://dev.proinvestor.com/forum/post/8006540https://dev.proinvestor.com/forum/post/8006540Fri, 10 Feb 2023 15:08:17 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Fri, 10 Feb 2023 15:08:07 GMT]]>Hansa Biopharma: Update ahead of 2023 – Gradual progress ahead

Just a moment...

favicon

(www.redeye.se)

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months.

]]>https://dev.proinvestor.com/forum/post/8006542https://dev.proinvestor.com/forum/post/8006542Fri, 10 Feb 2023 15:08:07 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Fri, 10 Feb 2023 05:14:03 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006539https://dev.proinvestor.com/forum/post/8006539Fri, 10 Feb 2023 05:14:03 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Thu, 09 Feb 2023 05:24:30 GMT]]>Godmorgen 🙂 Aps ja du har ret alle stigninger neutraliseres hurtigt øv

]]>https://dev.proinvestor.com/forum/post/8006548https://dev.proinvestor.com/forum/post/8006548Thu, 09 Feb 2023 05:24:30 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Wed, 08 Feb 2023 08:24:05 GMT]]>Interresant artikel med brug af Imlifidase udenfor nyre transplantation. Brugt off-label til en patient med AML (Acute myeloid leukemia). Imlifidase virkede som det skulle (som sædvanligt).https://ashpublications.org/blood/article/140/Supplement 1/8562/489191/Successful-Desensitization-of-Severe-Alloimmune

]]>https://dev.proinvestor.com/forum/post/8006538https://dev.proinvestor.com/forum/post/8006538Wed, 08 Feb 2023 08:24:05 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Wed, 08 Feb 2023 07:51:04 GMT]]>Helt enig;-)

]]>https://dev.proinvestor.com/forum/post/8006543https://dev.proinvestor.com/forum/post/8006543Wed, 08 Feb 2023 07:51:04 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Wed, 08 Feb 2023 07:29:58 GMT]]>Hansa virker “forpestet” 🙂 ALLE stigninger bliver omgående neutraliseret af et udsalg. Tålmodighed, men lidt frustrerende at se sælgerne kaste sig over aktien efter lidt stigning. 🙂

]]>https://dev.proinvestor.com/forum/post/8006536https://dev.proinvestor.com/forum/post/8006536Wed, 08 Feb 2023 07:29:58 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Wed, 08 Feb 2023 05:32:57 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006535https://dev.proinvestor.com/forum/post/8006535Wed, 08 Feb 2023 05:32:57 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Tue, 07 Feb 2023 05:25:15 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006537https://dev.proinvestor.com/forum/post/8006537Tue, 07 Feb 2023 05:25:15 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Mon, 06 Feb 2023 09:33:17 GMT]]>Kopieret fra Genmab chatten. Nr. 2 er god læsning :-).https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2023?itm_source=parsely-api

]]>https://dev.proinvestor.com/forum/post/8006532https://dev.proinvestor.com/forum/post/8006532Mon, 06 Feb 2023 09:33:17 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Mon, 06 Feb 2023 05:16:58 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006534https://dev.proinvestor.com/forum/post/8006534Mon, 06 Feb 2023 05:16:58 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sun, 05 Feb 2023 14:05:27 GMT]]>Gnsn kursmål (sidste 1,5 mdr) fra 6 store analysehuse er nu 212. Carnegie lavest og SEB højest. Og trenden er at de forhøjer nu.

]]>https://dev.proinvestor.com/forum/post/8006527https://dev.proinvestor.com/forum/post/8006527Sun, 05 Feb 2023 14:05:27 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sun, 05 Feb 2023 08:27:07 GMT]]>Pt. en aggregeret shortposition på i alt: 3,32%.

Det er 1,56M aktier (ca. 1566579 stk.) som skal købes tilbage på et tidspunkt.

]]>https://dev.proinvestor.com/forum/post/8006533https://dev.proinvestor.com/forum/post/8006533Sun, 05 Feb 2023 08:27:07 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 04 Feb 2023 20:34:06 GMT]]>SEB höjer riktkursen för Hansa Biopharma till 260 kronor (230), upprepar köp – BN

newsroom@finwire.se
Nyhetsbyrån Finwire

]]>https://dev.proinvestor.com/forum/post/8006529https://dev.proinvestor.com/forum/post/8006529Sat, 04 Feb 2023 20:34:06 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 04 Feb 2023 20:31:26 GMT]]>Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Call Transcript

Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ET

Access to this page has been denied

px-captcha

favicon

(seekingalpha.com)

Company Participants

Søren Tulstrup - President and CEO

Donato Spota - SVP and CFO

Conference Call Participants

Gonzalo Attali - ABG Sundal Collier

Zoe Karamanoli - RBC Capital Markets

Christopher Uhde - SEB

Johan Unne

]]>https://dev.proinvestor.com/forum/post/8006530https://dev.proinvestor.com/forum/post/8006530Sat, 04 Feb 2023 20:31:26 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 04 Feb 2023 06:30:39 GMT]]>Penser Access:

"Vårt nya motiverade värde är 210-220 kronor per aktie (240-250). Vi ser en fortsatt mycket stor uppsida i Hansa-aktien på sikt, men en tillväxt i produktförsäljning av Idefirix kommer att bli av yttersta vikt för att aktien ska prestera framöver".

]]>https://dev.proinvestor.com/forum/post/8006525https://dev.proinvestor.com/forum/post/8006525Sat, 04 Feb 2023 06:30:39 GMT<![CDATA[Reply to Hansa Biopharma — Februar 2023 on Sat, 04 Feb 2023 06:10:03 GMT]]>Hansa Biopharma - Presentation of Q4 interim report 2022 - 03.02.2023https://www.youtube.com/watch?v=PGIhqMK-Kzw&ab_channel=HCAndersenCapital

]]>https://dev.proinvestor.com/forum/post/8006528https://dev.proinvestor.com/forum/post/8006528Sat, 04 Feb 2023 06:10:03 GMT